Search
Dexamethasone Treatment Options
A collection of 1463 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States . Dexamethasone is used for conditions such as Multiple Myeloma, Postoperative Pain and Lymphoma.
637 - 648 of 1463
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
Terminated
Multiple myeloma (MM) accounts for more than 10% of all blood cancers and 1% of all cancers. The purpose of this study is to assess how safe lemzoparlimab is and how lemzoparlimab moves through the body of adult participants with MM when given with or without dexamethasone, and in combination with other anti-myeloma regimens. Adverse events and change in disease activity will be assessed.
Lemzoparlimab is an investigational drug being developed for the treatment of relapsed/refractory (R/R) MM.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: Sylvester Comprehensive Cancer Center /ID# 228817, Miami, Florida +31 locations
Conditions: Multiple Myeloma
Transverse Abdominus Plane Block Study
Withdrawn
Study the effect of laparoscopic guided TAP block on opioid consumption and associated costs using a mixture of dexmedetomidine, dexamethasone, and ropivacaine versus Liposomal bupivacaine (Exparel®) in patients who undergo elective minimally invasive colorectal surgery.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/03/2023
Locations: Rocky Mountain Regional VA Medical Center, Aurora, Colorado +2 locations
Conditions: Colorectal Disorders, Surgery
An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
Completed
The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either:
Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone.
Enrollment is closed for all groups.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: Local Institution - 0020, Birmingham, Alabama +120 locations
Conditions: Multiple Myeloma
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Completed
The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2023
Locations: Mayo Clinic, Jacksonville, Florida +3 locations
Conditions: Multiple Myeloma
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
Terminated
This is an open-label, multicenter study to confirm the safety and efficacy of durvalumab + daratumumab (D2) in subjects with relapsed and refractory multiple myeloma. This study will also explore the safety and efficacy of the addition of pomalidomide + dexamethasone to durvalumab + daratumumab (PD3).
On 05 Sep 2017, a Partial Clinical Hold was placed on this study by the United States (US) Food and Drug Administration (FDA). The decision by the FDA was based on data related to risks of anti-p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: City of Hope National Medical Center, Duarte, California +63 locations
Conditions: Multiple Myeloma
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
Terminated
The goal of this clinical research study is to learn if blinatumomab can help to control Richter Transformation (RT, a type of blood cancer). The safety of this drug will also be studied.
This is an investigational study. Blinatumomab is FDA approved and commercially available for the treatment of acute lymphoblastic leukemia (ALL). It is investigational to use blinatumomab to treat patients with RT. The study doctor can explain how the study drug is designed to work.
Up to 21 participants wil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Hematopoietic/Lymphoid Cancer, Richter's Transformation
A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients
Terminated
This is a randomized, two-period, cross-over Phase 2 study, comparing PK, and assessing safety and tolerability and efficacy of peripheral and central intravenous administration of melflufen in patients with RRMM. It is an international study, enrolling patients in US and Europe. The study will enroll patients following at least 2 lines of prior therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2023
Locations: The Oncology Institute of Hope & Innovation - Glendale, Glendale, California +9 locations
Conditions: RRMM
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Completed
The purpose of this study is to determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression free survival (PFS) in participants with relapsed and/or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2023
Locations: University of Arkansas Medical Sciences, Little Rock, Arkansas +23 locations
Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
Completed
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator. This purpose of this study is to show that the updated DEX PS DDS Applicator works in adult participants with macular edema due to retinal diseases.
The DEX PS DDS is approved for the treatment of macular edema. Participants will be placed into 1 of 2 groups, called treatment arms. Each group receives the same trea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2023
Locations: Global Research Management /ID# 238944, Glendale, California +6 locations
Conditions: Macular Edema
A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects
Terminated
This is an open-label, multi-center, bilateral, human factors study designed to evaluate the utilization and safety of a novel intracanalicular insertion device in healthy subjects and to evaluate the concentration of DEXTENZA in tears. Each subject's participation is expected to last for approximately 1 month from the DEXTENZA insertion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2023
Locations: Ocular Therapeutix, Inc., Sioux Falls, South Dakota
Conditions: Healthy
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Completed
The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone (PomDex) in Phase 1, and to provide a preliminary evaluation of the clinical activity of TAK-079 monotherapy in Phase 2a in participants with r/r MM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2023
Locations: City of Hope - Duarte, Duarte, California +6 locations
Conditions: Relapsed/Refractory, Multiple Myeloma
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
Withdrawn
This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, New Jersey (NJ) (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in patients with triple class refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/25/2023
Locations: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia +2 locations
Conditions: Multiple Myeloma, Refractory
637 - 648 of 1463